Sofia Donovan

Abstract PS2-12-06: BBO-10203, a first-in-class breaker of the RAS:PI3Kα interaction, inhibits tumor growth alone and in combination with fulvestrant or ribociclib in breast cancer models without inducing hyperglycemia

K. W. Sinkevicius, J. P. Stice, Cathy Zhang, Siyu Feng et autres

Abstract Aberrant activation of the PI3Kα pathway is one of the most frequent oncogenic events across human cancers and leads to promotion of tumor cell growth, survival, glucose metabolism, and acute resistance to numerous standard of care cancer therapies. Although PI3Kα inhibitors …

us (code pays fourni par la source)

Beyond the Initial Illness: Factors Associated with Recurrent Diarrhea in Malnourished Kenyan Children

Sofia Donovan

Thesis (Master's)--University of Washington, 2026

Abstract C082: BBO-10203, a first-in-class, orally bioavailable, selective breaker of the RAS:PI3Kα interaction inhibits tumor growth alone and in combination with KRAS inhibitors in KRAS mutant models without inducing hyperglycemia

Kerstin W. Sinkevicius, James P. Stice, Rui Xu, Cathy Zhang et autres

Abstract Aberrant activation of the PI3Kα pathway is one of the most frequent oncogenic events across human cancers and leads to promotion of tumor cell growth, survival, glucose metabolism, and acute resistance to numerous standard of care cancer therapies. While PI3Ka kinase …

us (code pays fourni par la source)

Abstract PS7-04: BBO-10203, a first-in-class, orally bioavailable, selective blocker of the PI3Kα:RAS interaction inhibits tumor growth alone and in combination with standard of care therapies in breast cancer models without inducing hyperglycemia

Kerstin W. Sinkevicius, James P. Stice, Erin Riegler, Siyu Feng et autres

Abstract Aberrant activation of the PI3Kα pathway is one of the most frequent oncogenic events across human cancers and leads to promotion of tumor cell growth, survival, glucose metabolism, and acute resistance to numerous standard of care cancer therapies. While small molecule …

BBO-10203 inhibits tumor growth without inducing hyperglycemia by blocking RAS-PI3Kα interaction

Dhirendra K. Simanshu, Rui Xu, James P. Stice, Daniel J. Czyzyk et autres

BBO-10203 is an orally available drug that covalently and specifically binds to the rat sarcoma (RAS)–binding domain of phosphoinositide 3-kinase α (PI3Kα), preventing its activation by HRAS, NRAS, and KRAS. It inhibited PI3Kα activation in tumors with oncogenic mutations in KRAS or …

us (code pays fourni par la source)

Scoping review of levonorgestrel pharmacokinetic data in special populations

Ana Krause, Sofia Donovan, Sunita Nolan, Stephen Hawes

The START team conducted a scoping review to map the existing literature on levonorgestrel pharmacokinetics in special population groups with pathophysiology theorized or understood to impact drug pharmacokinetics (e.g. undernutrition, liver disease, female reproductive tract abnormalities, gastrointestinal illnesses) and identify any gaps …

us (code pays fourni par la source)

Scoping review of levonorgestrel pharmacokinetic data in special populations

Ana Krause, Sunita Nolan, Sofia Donovan, Stephen Hawes

The START team conducted a scoping review to map the existing literature on levonorgestrel pharmacokinetics in special population groups with pathophysiology theorized or understood to impact drug pharmacokinetics (e.g. undernutrition, liver disease, female reproductive tract abnormalities, gastrointestinal illnesses) and identify any gaps …

Abstract RF02-02: BBO-10203, a first-in-class, orally bioavailable, selective covalent small molecule that inhibits RAS-driven PI3Kalpha activity without affecting glucose metabolism

Pedro J. Beltran, Simanshu Dhirendra, Rui Xu, Ming Chen et autres

Abstract PI3Kα is the most mutated kinase and the second most mutated oncogene in human cancer. Activation of PI3Ka can be achieved by receptor tyrosine kinases such as insulin receptor and insulin-like growth factor receptor 1 and/or by directly interacting with RAS …

us, ar (code pays fourni par la source)

Abstract P207: BBP-398, a potent, small molecule inhibitor of SHP2, enhances the response of established NSCLC xenografts to KRASG12C and mutEGFR inhibitors

James P. Stice, Sofia Donovan, Yuting Sun, Nancy E. Kohl et autres

Abstract Src homology 2 domain-containing phosphatase (SHP2), a ubiquitously expressed non-receptor tyrosine phosphatase, plays a critical role in the regulation of the MAPK signaling pathway and cellular proliferation. Activating mutations in SHP2 are associated with the development of multiple malignancies including leukemia, …

us (code pays fourni par la source)